Subset analysis of a randomized trial reveals high-dose daunorubicin sensitivity in extramedullary acute myeloid leukemia, highlighting potential therapeutic advantages.
Extramedullary (EM) disease is an unusual manifestation of de novo acute myeloid leukemia (AML) occurring in less than 10% of patients at diagnosis. 5] We describe the clinical, chromosomal, molecular and immunophenotypic characteristics, and the outcomes following standard-dose versus high-dose daunorubicin in induction.
No takes yet. Share an insight, caveat, or question.
Fernández et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: